{
    "clinical_study": {
        "@rank": "38357", 
        "acronym": "Flucocrypto", 
        "arm_group": {
            "arm_group_label": "oral treatment", 
            "arm_group_type": "Other", 
            "description": "Drug:   Fluconazole and flucytosine\nInduction treatment for 2 weeks:\nFluconazole (1600mg/j) + flucytosine (100 mg/kg/j) lumbar punctures to control intracranial pressure Consolidation treatment for 8 weeks: fluconazole (800 mg/j)"
        }, 
        "brief_summary": {
            "textblock": "The aim of the trial is to demonstrate that in a sub-Saharan African setting, the\n      association of:\n\n        1. Oral treatment : high dose of fluconazole (1600mg/d) associated with flucytosine (100\n           mg/kg/j) as induction therapy\n\n        2. lumbar punctures to control intracranial pressure\n\n      can decrease mortality rate below 35% at 10 weeks.\n\n      This is a non-randomized open label pilot study, with standardized management of\n      cryptococcoses meningitis and follow-up in Burundi and Ivory Coast. A total of 41 patients\n      will be enrolled."
        }, 
        "brief_title": "Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cryptococcal Meningitis", 
            "HIV"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Meningitis", 
                "Meningitis, Cryptococcal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  > 18 years\n\n          -  HIV Infection\n\n          -  First episode of cryptococcal meningitis on basis CSF India ink and/or CSF\n             cryptococcal antigen.\n\n          -  Glasgow > 9 after lumbar punctures\n\n          -  Absence of peripheral focal deficit in the limbs\n\n          -  informed consent signed\n\n        Exclusion Criteria:\n\n          -  Hemoglobin <7.5 g / dl;\n\n          -  neutrophils count <500/mm3;\n\n          -  Platelets count <50 000/mm3;\n\n          -  transaminases > 5 times upper limit of normal;\n\n          -  Troubles with severe mental alertness Glasgow <9 after the initial lumbar puncture;\n\n          -  focal neurological deficit in the limbs;\n\n          -  Pregnancy or lactation on going;\n\n          -  Ongoing systemic antifungal treatment;\n\n          -  History of cryptococcal meningitis;\n\n          -  Ongoing rifampicin and ritonavir treatment;\n\n          -  Subject participating in another study with a risk of mutual interference on the\n             interpretation of results."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01715922", 
            "org_study_id": "ANRS 12257 Flucocrypto"
        }, 
        "intervention": [
            {
                "arm_group_label": "oral treatment", 
                "description": "Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)", 
                "intervention_name": "Fluconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "oral treatment", 
                "description": "Flucytosine (100 mg/kg/j) for 2 weeks", 
                "intervention_name": "Flucytosine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "oral treatment", 
                "description": "lumbar punctures to control intracranial pressure", 
                "intervention_name": "lumbar punctures", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluconazole", 
                "Flucytosine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cryptococcal meningitis", 
            "HIV Infections", 
            "Oral treatment", 
            "High dose of fluconazole", 
            "Flucytosine", 
            "Burundi", 
            "Ivory Coast"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "link": {
            "description": "Sponsor web page", 
            "url": "http://www.anrs.fr"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bujumbura", 
                        "country": "Burundi"
                    }, 
                    "name": "CHU Kamenge"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bujumbura", 
                        "country": "Burundi"
                    }, 
                    "name": "H\u00f4pital Prince R\u00e9gent Charles"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bururi", 
                        "country": "Burundi"
                    }, 
                    "name": "H\u00f4pital g\u00e9n\u00e9ral"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kayanza", 
                        "country": "Burundi"
                    }, 
                    "name": "H\u00f4pital g\u00e9n\u00e9ral"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muyinga", 
                        "country": "Burundi"
                    }, 
                    "name": "H\u00f4pital g\u00e9n\u00e9ral"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Abidjan", 
                        "country": "C\u00f4te D'Ivoire"
                    }, 
                    "name": "Service de Maladies Infectieuses & Tropicales - H\u00f4pital Triechville"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Abidjan", 
                        "country": "C\u00f4te D'Ivoire"
                    }, 
                    "name": "Service de Neurologie - H\u00f4pital Cocody"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Burundi", 
                "C\u00f4te D'Ivoire"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective Pilot Study to Evaluate a Standardized Management of Cryptococcal Meningitis in Patients Infected With HIV in Sub-Saharan Africa Involving an Initial Combination Therapy With Fluconazole and Flucytosine in High Doses, Complemented by Repeat Lumbar Punctures", 
        "overall_official": [
            {
                "affiliation": "Hopital Avicenne, Service des maladies infectieuses, Paris, france", 
                "last_name": "Olivier Bouchaud, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "CHU Kamenge, Bujumbura, Burundi", 
                "last_name": "Th\u00e9odore Niyangobo, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Hopital Avicenne, Service des maladies infectieuses, Paris, france", 
                "last_name": "Am\u00e9lie Chabrol, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHU Triechville", 
                "last_name": "Kakou AKA, Professor", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Burundi: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mortality rate", 
            "safety_issue": "Yes", 
            "time_frame": "10 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01715922"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mortality rate", 
                "safety_issue": "Yes", 
                "time_frame": "14 days and 24 weeks"
            }, 
            {
                "measure": "Percentage of patients with negative cerebrospinal fluid (CSF) cultures", 
                "safety_issue": "No", 
                "time_frame": "14 days and 10 weeks"
            }, 
            {
                "measure": "Number of relapses of cryptococcal throughout the monitoring period", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "The IRIS diagnosis criteria will be those given in: Bicanic T, et al. Immune Reconstitution Inflammatory Syndrome in HIV-associated cryptococcal meningitis: a prospective study, J Acquir Immune Defic Syndr 2009; 51:130-134.", 
                "measure": "Number of \"Immune Reconstitution Inflammatory Syndrome\" (IRIS) throughout the monitoring period", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "measure": "Number and severity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "measure": "Cerebrospinal fluid  pressure evolution", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "measure": "Percentage of patients with undetectable viral load", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "CD4 count", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Concentration of  flucytosine in cerebrospinal fluid", 
                "safety_issue": "No", 
                "time_frame": "28 days or 10  weeks"
            }, 
            {
                "description": "on urines, plasma, CSF and whole blood fingerstick", 
                "measure": "Sensitivity of cryptococcal antigen by strip method LFA (lateral-flow immunoassay)", 
                "safety_issue": "No", 
                "time_frame": "at study entry"
            }, 
            {
                "measure": "CSF total volume discharged", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "measure": "Number of lumbar punctures performed", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "measure": "Concentration of fluconazole in plasma", 
                "safety_issue": "No", 
                "time_frame": "28 days or 10  weeks"
            }, 
            {
                "measure": "Concentration of fluconazole in cerebrospinal fluid", 
                "safety_issue": "No", 
                "time_frame": "28 days or 10  weeks"
            }, 
            {
                "measure": "Concentration of flucytosine in plasma", 
                "safety_issue": "No", 
                "time_frame": "28 days or 10  weeks"
            }, 
            {
                "description": "MICs of fluconazole for cryptococcus strains, if CSF cultures ar positive at 28 days or 10 weeks or in case of relapse", 
                "measure": "MICs of fluconazole", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "source": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "CHU Kamenge, BURUNDI", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hospital Avicenne", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Institut Pasteur", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "H\u00f4pital Necker-Enfants Malades", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Institut de M\u00e9decine et Epid\u00e9miologie Appliqu\u00e9e (IMEA)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "H\u00f4pital de Treichville", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "H\u00f4pital Cocody", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}